利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

67 条记录 (耗时 0.048 秒)

    Method for identifying useful polypeptide vaccines
    32.
    发明授权
    Method for identifying useful polypeptide vaccines 失效
    鉴定有用的多肽疫苗的方法

    公开(公告)号：US5200320A

    公开(公告)日：1993-04-06

    申请号：US130036

    申请日：1987-12-07

    申请人： Alessandro Sette ,  Soren Buus ,  Howard M. Grey

    发明人： Alessandro Sette ,  Soren Buus ,  Howard M. Grey

    IPC分类号： G01N33/569 ,  G01N33/68

    CPC分类号： G01N33/56977 ,  G01N33/68

    摘要： A method of identifying potential polypeptide vaccines to an agent, such as viruses, bacteria, and parasites. A critical binding segment of a first polypeptide known to bind to a first MHC type, is ascertained. The effect of replacing each of the amino acids in the critical segment, upon binding of that segment to the first MHC type, is evaluated. Following this, a protein produced by the agent is scanned for at least one trial amino acid sequence which the foregoing evaluation indicates will be a good binder to the first MHC type. When a potentially good binding sequence is found, a polypeptide containing such sequence can be evaluated as a synthetic vaccine.

    摘要翻译： 将潜在的多肽疫苗鉴定为诸如病毒，细菌和寄生虫的试剂的方法。 确定已知结合第一MHC类型的第一多肽的关键结合片段。 评估在将该片段与第一MHC类型结合时，将临界片段中的每个氨基酸替换的效果。 随后，将由该试剂产生的蛋白质扫描至少一个试验氨基酸序列，其中上述评估指示为第一MHC型的良好粘合剂。 当发现潜在的良好结合序列时，可以将含有该序列的多肽评价为合成疫苗。

    Alteration of immune response using pan DR-binding peptides
    38.
    发明授权
    Alteration of immune response using pan DR-binding peptides 失效
    使用泛DR-结合肽改变免疫反应

    公开(公告)号：US07202351B1

    公开(公告)日：2007-04-10

    申请号：US09709774

    申请日：2000-11-08

    申请人： Alessandro Sette ,  Federico Gaeta ,  Howard M. Grey ,  John Sidney ,  Jeffery L. Alexander

    发明人： Alessandro Sette ,  Federico Gaeta ,  Howard M. Grey ,  John Sidney ,  Jeffery L. Alexander

    IPC分类号： C07H21/04

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/001 ,  C07K14/005 ,  C07K14/70539 ,  C12N2730/10122 ,  Y10S530/868

    摘要： The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

    摘要翻译： 本发明提供抑制或诱导患者T细胞活化的组合物和方法。 所述方法包括施用治疗有效剂量的药物组合物，其包含药学上可接受的载体和约4至约20个残基的肽，其结合基本上所有DR基因座全部等位基因编码的MHC分子上的抗原结合位点。 这些肽被称为pan DR结合肽。 泛DR结合肽可用于抑制与免疫病理学相关的免疫应答，例如自身免疫，同种异体移植排斥和过敏反应。 肽也可以与CTL肽组合使用以增强CTL应答。